Synthesis and structure of the platelet aggregation factor thromboxane A2.
In 1975, Hamberg et al. reported evidence for the existence of an unstable platelet-aggregating factor which they named thromboxane A2 (TXA2) and for which they proposed a novel bicyclic oxetane structure (1, below) based on the short half-life of the factor (t1/2 (37 degrees C) = 32 s at pH 7.4) and the isolation of degradation products related to thromboxane (TXB2) (2, below). As natural TXA2 has not yet been isolated and characterized as a pure compound, we have synthesized the proposed structure (1) from TXB2 and compared its biological properties with those of authentic, biologically generated material. Here we present evidence that synthetic material having structure (1) is indistinguishable from platelet-derived TXA2 in various biological assays and that the proposed structure (1) for TXA2 is correct.
D001792:Blood Platelets / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D011450:Prostaglandin Endoperoxides, Synthetic / Q000494:pharmacology; D044262:Prostaglandin H2; D011463:Prostaglandins H / Q000494:pharmacology; D013928:Thromboxane A2 / Q000138:chemical synthesis* / Q000494:pharmacology; D013931:Thromboxanes / Q000138:chemical synthesis*
D011450:Prostaglandin Endoperoxides, Synthetic; D011463:Prostaglandins H; D013931:Thromboxanes; D044262:Prostaglandin H2; D013928:Thromboxane A2